AFWG shall not bear any responsibility for any content on such sites. Any link to a third-party site does not constitute an endorsement of the third party, their site or services. AFWG also makes no warranties as to the content of such sites.
Would you like to continue?
One of the main risk factors contributing to mortality of patients with invasive fungal infections (IFIs) is inadequate antifungal therapy. This could be from delayed treatment, inappropriate choice of antifungal agent, insufficient dose or poor attention to drug PK/PD. Individual patients require individualized, optimized therapy.
Delivered by Professor Deborah Marriott, this module examines the basics of echinocandin PK and PD, makes a case for echinocandin therapeutic drug monitoring (TDM), and discusses dosing recommendations for critically ill and obese patients.